Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Instituto de Investigación Biomédica de Salamanca
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
Institute of Hematology and Blood Transfusion, Czech Republic
Hoosier Cancer Research Network
New York Medical College
University of Alabama at Birmingham
University of Alabama at Birmingham
Washington University School of Medicine
Centre Antoine Lacassagne
Therapeutic Advances in Childhood Leukemia Consortium
Charles Drew University of Medicine and Science
Children's Hospital of Philadelphia
Children's Hospital of Philadelphia
Institute of Cancer Research, United Kingdom
University of Cincinnati
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
M.D. Anderson Cancer Center
Institut Claudius Regaud
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Fundación de investigación HM
University of Wisconsin, Madison
National Cancer Center Hospital East
Northwestern University
St. Jude Children's Research Hospital
Icahn School of Medicine at Mount Sinai
Massachusetts General Hospital
University of California, San Francisco
Nationwide Children's Hospital
University of Florida
Dana-Farber Cancer Institute
University of California, San Francisco
Johns Hopkins University
M.D. Anderson Cancer Center
Milton S. Hershey Medical Center